ArticleBMC medicine2015
Validation of a novel point of care testing device for sickle cell disease.
Article in BMC medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07009821 (SCREENING EmoCamp_ Analysis of Major Haemoglobinopathies Among Newborns in the Campania Region), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SCREENING EmoCamp_ Analysis of Major Haemoglobinopathies Among Newborns in the Campania Region
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Sustainability of newborn screening for sickle cell disease in resource-poor countries: A systematic review.PloS one · 2024Pooled it
- Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.American journal of hematology · 2019Trial
- Acoustic probing of new biomarkers for rapid sickle cell disease screening.Lab on a chip · 2026Article
- Diagnostic accuracy of the sickle SCANAnnals of hematology · 2026Article
- Uganda's Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation.Pediatric health, medicine and therapeutics · 2026Article
- Sickle Cell Disease and Gene Therapy Among African Americans: A Dilemma and Challenge.Journal of racial and ethnic health disparities · 2025Review
- Diagnostic accuracy of HemoTypeSC for detecting sickle cell disease in newborns: A multicentric study.The Indian journal of medical research · 2025Article
- Evaluation of low-cost techniques to detect sickle cell disease and β-thalassemia: an open-label, international, multicentre study.The Lancet regional health. Southeast Asia · 2025Article
- Operational Feasibility of Point-of-Care Testing for Sickle Cell Disease in Resource-Limited Settings of Tribal Sub-Plan Region of India.Diagnostics (Basel, Switzerland) · 2025Article
- Feasibility analysis of the SICKLECHECK™ test kit for rapid screening of sickle cell disease at a County Referral Hospital in Kenya.African journal of laboratory medicine · 2025Article
- Article
- Sickle cell allele distribution in southern India: a population-based study in a rural-tribal context.BMJ public health · 2025Article
- Newborn screening initiatives for sickle cell disease in Africa.Hematology. American Society of Hematology. Education Program · 2024Review
- Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and trait blood samples at point of care.Bioengineering & translational medicine · 2024Article
- Determination of birth prevalence of sickle cell disease using point of care test HemotypeSC™ at Rundu Hospital, Namibia.BMC pediatrics · 2024Article
- Point-of-Care Diagnostic Test for Beta-Thalassemia.Biosensors · 2024Article
- Versatility of reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) from diagnosis of early pathological infection to mutation detection in organisms.Molecular biology reports · 2024Review
- Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti.Blood advances · 2024Article
- Evaluation of a point-of-care rapid diagnostic test kit (SICKLECHECK) for screening of sickle cell diseases.PloS one · 2024Article
- Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease is one of the most common inherited blood disorders. Universal screening and early intervention have significantly helped to reduce childhood mortality in high-resource countries. However, persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings. To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait at the point of care without electricity or advanced equipment.
methodsThis study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S, and C allowing for detection of results with the naked eye.
resultsLaboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at the point of care for further validation. This test detected the correct A, S, and C presence with an overall diagnostic accuracy of 99 % at the bedside.
conclusionThe Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation testing will be conducted in newborns in resource-poor settings in upcoming studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.